Novo Nordisk has released phase 3 data from the STEP Young trial, marking the first time semaglutide has been tested in children aged 6 to under 12 living with obesity. The results are striking: after 68 weeks of treatment combined with lifestyle modification, 40.4% of children receiving semaglutide were no longer classified as obese, compared with none in the placebo group.
This trial met its primary endpoint, demonstrating superior BMI reduction in the semaglutide group. Importantly, safety and tolerability were consistent with adult and adolescent studies, with no new concerns identified for growth or pubertal development. Given that more than 85% of participants entered the trial with severe obesity (class II or III), the findings suggest semaglutide could become a powerful tool in pediatric obesity care, where effective options are scarce.
Clinical Breakthrough in Pediatric Obesity
Experts emphasize the urgency of addressing childhood obesity, which carries immediate health risks and strongly predicts adult obesity and related complications. Dr. Ania M. Jastreboff of Yale noted that most children in the trial began with severe obesity, yet nearly two in five reduced their BMI percentile below the obesity threshold within about a year.
Children living with obesity face cardiovascular risk factors, depression, eating disorders, and bullying, with quality of life comparable to children undergoing cancer treatment. Without intervention, these conditions track into adulthood, shortening life expectancy. The STEP Young data therefore represent not only a clinical milestone but also a potential shift in how pediatric obesity is treated worldwide.
The Global Epidemic Market Angle: Novo Nordisk’s Next Frontier
Beyond the clinical impact, the trial underscores Novo Nordisk’s positioning in a massive and expanding market. In 2025, an estimated 177 million children aged 5 to 19 were living with obesity, a figure projected to rise to 228 million by 2040. By moving aggressively into pediatric care, Novo Nordisk is establishing itself as a first‑mover in securing early‑life market share within the global obesity epidemic.
This strategy highlights how the pharmaceutical industry is adapting to the crisis as it shifts younger, blending public health urgency with business opportunity. For Novo Nordisk, semaglutide’s pediatric success could open a new frontier in obesity medicine, cementing its role as a dominant player in both clinical and commercial landscapes.
Detailed STEP Young results will be presented at ObesityWeek 2026 in Washington, D.C., this November.
1 Response